ImetelChat

Share price and such are never a topic here. Perhaps rightfully so. Suffice it to say that it is NOT a good time for the lowly investor in this co. And I do not see that changing any time soon.

The extended time frames are disappointing. But the idea of a sit down with the FDA and trying an end run around needing a dual trial for MF given the current stats, is a novel idea worth pursuing. Kudos for the crew that came up with it

At some point in this progression it seems as though the left hand has no idea of what the right hand is doing. Rhetorical question is why is there such a disconnect between the stats offered by the sub-group of 13, and the FDA's apparent indifference to the same? OS is the standard. As it should be...

And this CT filing adds to the mystery.

Was said that it would take a full year to return all data. Dated from the 9/28 CD, that puts full return in the Fall. Would/could Geron open a P3 without that data secured and analyzed? Seems the $$ burn rate, if extended until sometime in the Fall, would necessitate the share offering sooner rathe...

My apology. You are correct. Fast track, no. Orphan status, yes.
Blinded by wishful thinking, I suppose.

EMA granted fast track to IMET in '15..... IMO approval for MF will come from them before the FDA.

Have to give him some kudos for his choices here and w/ Rizo etc. The CRO and the Dr. are top of the line. Redemption is full his if he can pull this off.

Without a major firms marketing, sales force, contacts and it's own reputation, approval of this drug is, in and of itself, not a blanket guarantee that it will have a commercial success. One of the downsides of the loss of the JnJ partnership. Going it alone, through the P3, and beyond ....to the m...

Once again, thank you for your efforts. Much Appreciated.

Thank You.

Someone with more knowledge than I, please explain how those Pharmas that have taken out combo patents, using Imet paired with their own drug, can do so without a license or at least some kind of contractual agreement with Geron? Thanks in advance.

Your are to be commended for your insightful letter and the intents behind it. Sad to realize that the company has a standing policy not to respond, except in boiler plate, cliche hyperbole. But good effort anyway.

Constantly amazed at the plodding, hesitant and (still) cumbersome process(es) used by the FDA. Granted, protection is their mission. And appreciated. However, from a patients view point, if a drug candidate has controllable toxicity, and statistically gives just ONE MORE DAY to live, where is the j...

Hardly a spotlight.

Honest enthusiasm is warranted for both patients and the stock. Impressive.

The economics of this company while controversial, are certainly important. That they are not discussed here is polite and respectful of the "science" emphasis of this board.

Seems we are facing yet ANOTHER binary decision. Is the data good enough to proceed, or did will we find that JnJ bailed because of significantly negative stats? Historically we have not fared all that well when it comes to go/no-go decisions. Just a hope, expressed here, that the coin flips in our ...

You give color to the mindless,endless frustrations around this company. Like you I've no idea of the complexity both technically and legally around the cessation of the CD and transfer of the accumulated data. There is the compassionate consideration as well. Will the current patients be able to re...

Is this the contract you are referring to? This was posted here late last month.
https://www.sec.gov/Archives/edgar/data ... ex10d1.htm